Abstract
Intermittent claudication (IC) is a common symptom associated with peripheral arterial disease that has a benign course in most patients. The primary therapy for patients with IC includes antiplatelet therapy, statins, risk factor modification, and supervised exercise. Of the patients who adhere to this regimen, <5% will develop chronic limb-threatening ischemia.1,2 As such, any surgical intervention for IC should lead to a sustained benefit. This was clearly defined in the Society for Vascular Surgery (SVS) practice guidelines for the management of IC, which recommended that an intervention should have a >50% likelihood of clinical efficacy for ≥2 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
